{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T08:24:02Z","timestamp":1792657442435,"version":"4.5.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100001491","name":"Belgian American Educational Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007311","name":"Cleveland Clinic Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007311","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajconline.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.amjcard.2024.01.009","type":"journal-article","created":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T07:02:05Z","timestamp":1706166125000},"page":"66-76","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Race, Genotype, and Prognosis in Black Patients With Transthyretin Cardiac Amyloidosis"],"prefix":"10.1016","volume":"216","author":[{"given":"Rola","family":"Khedraki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Saef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter","family":"Martens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trejeeve","family":"Martyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidiya","family":"Sul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rory","family":"Hachamovitch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Ives","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry D.","family":"Estep","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.H. Wilson","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mazen","family":"Hanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjcard.2024.01.009_bib0001","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.jacc.2016.06.053","article-title":"AL (light-chain) cardiac amyloidosis: a review of diagnosis and therapy","volume":"68","author":"Falk","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2024.01.009_bib0002","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1097\/HCO.0000000000000953","article-title":"Cardiac amyloidosis: an update on diagnosis, current therapy, and future directions","volume":"37","author":"Khedraki","year":"2022","journal-title":"Curr Opin Cardiol"},{"key":"10.1016\/j.amjcard.2024.01.009_bib0003","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1002\/ehf2.12518","article-title":"Transthyretin cardiac amyloidosis: an update on diagnosis and treatment","volume":"6","author":"Yamamoto","year":"2019","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.amjcard.2024.01.009_bib0004","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1161\/CIRCULATIONAHA.115.018852","article-title":"Heart failure resulting from age-related cardiac amyloid disease associated with wild-type transthyretin: a prospective, observational cohort study","volume":"133","author":"Connors","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2024.01.009_bib0005","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.jacc.2016.06.033","article-title":"Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system","volume":"68","author":"Grogan","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2024.01.009_bib0006","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.113.000098","article-title":"Senile systemic amyloidosis: clinical features at presentation and outcome","volume":"2","author":"Pinney","year":"2013","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.amjcard.2024.01.009_bib0007","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1750-1172-8-31","article-title":"Guideline of transthyretin-related hereditary amyloidosis for clinicians","volume":"8","author":"Ando","year":"2013","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.amjcard.2024.01.009_bib0008","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1007\/s004390050199","article-title":"Revised transthyretin Ile 122 allele frequency in African-Americans","volume":"98","author":"Jacobson","year":"1996","journal-title":"Hum Genet"},{"key":"10.1016\/j.amjcard.2024.01.009_bib0009","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1080\/13506120500107162","article-title":"A prospective evaluation of the transthyretin Ile122 allele frequency in an African-American population","volume":"12","author":"Yamashita","year":"2005","journal-title":"Amyloid"},{"key":"10.1016\/j.amjcard.2024.01.009_bib0010","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/gim.2016.200","article-title":"Transthyretin V122I (pV142I)* cardiac amyloidosis: an age-dependent autosomal dominant cardiomyopathy too common to be overlooked as a cause of significant heart disease in elderly African Americans","volume":"19","author":"Buxbaum","year":"2017","journal-title":"Genet Med"},{"key":"10.1016\/j.amjcard.2024.01.009_bib0011","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2019.17935","article-title":"Association of the V122I hereditary transthyretin amyloidosis genetic variant with heart failure among individuals of African or Hispanic\/latino ancestry","volume":"322","author":"Damrauer","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.amjcard.2024.01.009_bib0012","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.116.003352","article-title":"Afro-Caribbean heart failure in the United Kingdom: cause, outcomes, and ATTR V122I cardiac amyloidosis","volume":"9","author":"Dungu","year":"2016","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.amjcard.2024.01.009_bib0013","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s10741-021-10098-6","article-title":"Clinical comparison of V122I genotypic variant of transthyretin amyloid cardiomyopathy with wild-type and other hereditary variants: a systematic review","volume":"27","author":"Goyal","year":"2022","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.amjcard.2024.01.009_bib0014","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.ahj.2009.08.006","article-title":"Cardiac amyloidosis in African Americans: comparison of clinical and laboratory features of transthyretin V122I amyloidosis and immunoglobulin light chain amyloidosis","volume":"158","author":"Connors","year":"2009","journal-title":"Am Heart J"},{"key":"10.1016\/j.amjcard.2024.01.009_bib0015","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.ahj.2012.04.015","article-title":"Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: the Transthyretin Amyloidosis Cardiac Study (TRACS)","volume":"164","author":"Ruberg","year":"2012","journal-title":"Am Heart J"},{"key":"10.1016\/j.amjcard.2024.01.009_bib0016","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.jchf.2022.06.006","article-title":"Racial and genetic differences in presentation of transthyretin amyloid cardiomyopathy with impaired left ventricular function","volume":"10","author":"Martyn","year":"2022","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.amjcard.2024.01.009_bib0017","article-title":"ASNC\/AHA\/ASE\/EANM\/HFSA\/ISA\/SCMR\/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: part 1 of 2-evidence base and standardized methods of imaging","volume":"14","author":"Dorbala","year":"2021","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.amjcard.2024.01.009_bib0018","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"370","author":"von Elm","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2024.01.009_bib0019","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1016\/j.ijsu.2014.07.013","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies","volume":"12","author":"von Elm","year":"2014","journal-title":"Int J Surg"},{"key":"10.1016\/j.amjcard.2024.01.009_bib0020","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1093\/eurheartj\/ehx589","article-title":"A new staging system for cardiac transthyretin amyloidosis","volume":"39","author":"Gillmore","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2024.01.009_bib0021","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1161\/CIRCULATIONAHA.118.038169","article-title":"Natural history, quality of life, and outcome in cardiac transthyretin amyloidosis","volume":"140","author":"Lane","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2024.01.009_bib0022","doi-asserted-by":"crossref","first-page":"229","DOI":"10.2217\/ahe.13.10","article-title":"Comparison of cardiac amyloidosis due to wild-type and V122I transthyretin in older adults referred to an academic medical center","volume":"9","author":"Givens","year":"2013","journal-title":"Aging Health"},{"key":"10.1016\/j.amjcard.2024.01.009_bib0023","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jacc.2016.03.596","article-title":"Genotype and phenotype of transthyretin cardiac amyloidosis: THAOS (transthyretin amyloid outcome survey)","volume":"68","author":"Maurer","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2024.01.009_bib0024","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.jacc.2016.09.987","article-title":"Val122Ile mt-ATTR has a worse survival than wt-ATTR cardiac amyloidosis","volume":"69","author":"Singh","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2024.01.009_bib0025","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1093\/eurheartj\/ehz905","article-title":"Echocardiographic phenotype and prognosis in transthyretin cardiac amyloidosis","volume":"41","author":"Chacko","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2024.01.009_bib0026","doi-asserted-by":"crossref","first-page":"3942","DOI":"10.1002\/ehf2.12989","article-title":"Disease progression in cardiac transthyretin amyloidosis is indicated by serial calculation of National Amyloidosis Centre transthyretin amyloidosis stage","volume":"7","author":"Law","year":"2020","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.amjcard.2024.01.009_bib0027","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.cardfail.2021.12.016","article-title":"Racial differences in Val122Ile-associated transthyretin cardiac amyloidosis","volume":"28","author":"Batra","year":"2022","journal-title":"J Card Fail"},{"key":"10.1016\/j.amjcard.2024.01.009_bib0028","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.cardfail.2022.01.004","article-title":"Biology or disparity? Untangling racial differences in Val122Ile transthyretin cardiac amyloidosis","volume":"28","author":"Kittleson","year":"2022","journal-title":"J Card Fail"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914924000596?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914924000596?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T10:08:46Z","timestamp":1762078126000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914924000596"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":28,"alternative-id":["S0002914924000596"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2024.01.009","relation":{},"ISSN":["0002-9149"],"issn-type":[{"value":"0002-9149","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Race, Genotype, and Prognosis in Black Patients With Transthyretin Cardiac Amyloidosis","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjcard.2024.01.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}